261 related articles for article (PubMed ID: 25816016)
1. Folate receptor-α (FOLR1) expression and function in triple negative tumors.
Necela BM; Crozier JA; Andorfer CA; Lewis-Tuffin L; Kachergus JM; Geiger XJ; Kalari KR; Serie DJ; Sun Z; Moreno-Aspitia A; O'Shannessy DJ; Maltzman JD; McCullough AE; Pockaj BA; Cunliffe HE; Ballman KV; Thompson EA; Perez EA
PLoS One; 2015; 10(3):e0122209. PubMed ID: 25816016
[TBL] [Abstract][Full Text] [Related]
2. Folate Receptor Alpha Expression Is Associated With Increased Risk of Recurrence in Triple-negative Breast Cancer.
Ginter PS; McIntire PJ; Cui X; Irshaid L; Liu Y; Chen Z; Shin SJ
Clin Breast Cancer; 2017 Nov; 17(7):544-549. PubMed ID: 28410844
[TBL] [Abstract][Full Text] [Related]
3. Folate receptor α associated with triple-negative breast cancer and poor prognosis.
Zhang Z; Wang J; Tacha DE; Li P; Bremer RE; Chen H; Wei B; Xiao X; Da J; Skinner K; Hicks DG; Bu H; Tang P
Arch Pathol Lab Med; 2014 Jul; 138(7):890-5. PubMed ID: 24028341
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological and immunohistochemical characteristics of breast cancer patients from Northeast India with special reference to triple negative breast cancer: A prospective study.
Sultana R; Kataki AC; Barthakur BB; Sarma A; Bose S
Curr Probl Cancer; 2020 Oct; 44(5):100556. PubMed ID: 32044043
[TBL] [Abstract][Full Text] [Related]
5. Differences in clinical importance of Bcl-2 in breast cancer according to hormone receptors status or adjuvant endocrine therapy.
Honma N; Horii R; Ito Y; Saji S; Younes M; Iwase T; Akiyama F
BMC Cancer; 2015 Oct; 15():698. PubMed ID: 26472348
[TBL] [Abstract][Full Text] [Related]
6. Association of increased osteopontin and splice variant-c mRNA expression with HER2 and triple-negative/basal-like breast carcinomas subtypes and recurrence.
Ortiz-Martínez F; Perez-Balaguer A; Ciprián D; Andrés L; Ponce J; Adrover E; Sánchez-Payá J; Aranda FI; Lerma E; Peiró G
Hum Pathol; 2014 Mar; 45(3):504-12. PubMed ID: 24440093
[TBL] [Abstract][Full Text] [Related]
7. Anti-Folate Receptor Alpha-Directed Antibody Therapies Restrict the Growth of Triple-negative Breast Cancer.
Cheung A; Opzoomer J; Ilieva KM; Gazinska P; Hoffmann RM; Mirza H; Marlow R; Francesch-Domenech E; Fittall M; Dominguez Rodriguez D; Clifford A; Badder L; Patel N; Mele S; Pellizzari G; Bax HJ; Crescioli S; Petranyi G; Larcombe-Young D; Josephs DH; Canevari S; Figini M; Pinder S; Nestle FO; Gillett C; Spicer JF; Grigoriadis A; Tutt ANJ; Karagiannis SN
Clin Cancer Res; 2018 Oct; 24(20):5098-5111. PubMed ID: 30068707
[No Abstract] [Full Text] [Related]
8. Genomic regulation of invasion by STAT3 in triple negative breast cancer.
McDaniel JM; Varley KE; Gertz J; Savic DS; Roberts BS; Bailey SK; Shevde LA; Ramaker RC; Lasseigne BN; Kirby MK; Newberry KM; Partridge EC; Jones AL; Boone B; Levy SE; Oliver PG; Sexton KC; Grizzle WE; Forero A; Buchsbaum DJ; Cooper SJ; Myers RM
Oncotarget; 2017 Jan; 8(5):8226-8238. PubMed ID: 28030809
[TBL] [Abstract][Full Text] [Related]
9. Folate Receptor Alpha Immunohistochemistry in Cytology Specimens of Metastatic Breast Carcinoma.
Sheikh UN; Cohen C; Siddiqui MT
Acta Cytol; 2015; 59(4):298-304. PubMed ID: 26413911
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of folate binding protein and mesothelin are associated with uterine serous carcinoma.
Dainty LA; Risinger JI; Morrison C; Chandramouli GV; Bidus MA; Zahn C; Rose GS; Fowler J; Berchuck A; Maxwell GL
Gynecol Oncol; 2007 Jun; 105(3):563-70. PubMed ID: 17400285
[TBL] [Abstract][Full Text] [Related]
11. Utility of folate receptor alpha immunohistochemistry in cytology specimens of metastatic breast carcinoma, metastatic serous carcinoma of Müllerian origin, and primary lung adenocarcinoma.
Sheikh UN; Cohen C; Siddiqui MT
Diagn Cytopathol; 2016 May; 44(5):369-76. PubMed ID: 26875861
[TBL] [Abstract][Full Text] [Related]
12. Differential expression of folate receptor 1 in medulloblastoma and the correlation with clinicopathological characters and target therapeutic potential.
Liu H; Sun Q; Zhang M; Zhang Z; Fan X; Yuan H; Li C; Guo Y; Ning W; Sun Y; Song Y; Yu C
Oncotarget; 2017 Apr; 8(14):23048-23060. PubMed ID: 28416738
[TBL] [Abstract][Full Text] [Related]
13. A systematic review and meta-analysis of higher expression of folate receptor alpha (FOLR1) predicts poor cancer prognosis.
Liu Y; Lian T; Yao Y
Biomarkers; 2020 Jul; 25(5):367-374. PubMed ID: 32421366
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of folate receptor 1 (FOLR1) mRNA expression, its specific promoter methylation and global DNA hypomethylation in type I and type II ovarian cancers.
Notaro S; Reimer D; Fiegl H; Schmid G; Wiedemair A; Rössler J; Marth C; Zeimet AG
BMC Cancer; 2016 Aug; 16():589. PubMed ID: 27485273
[TBL] [Abstract][Full Text] [Related]
15. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
16. Triple Negative Breast Cancer: Expression of Folate Receptor Alpha in Indian population.
Gajaria P; Kadu V; Patil A; Desai S; Shet T
Ann Diagn Pathol; 2020 Dec; 49():151598. PubMed ID: 32919338
[TBL] [Abstract][Full Text] [Related]
17. Nanoparticle targeted folate receptor 1-enhanced photodynamic therapy for lung cancer.
Kato T; Jin CS; Ujiie H; Lee D; Fujino K; Wada H; Hu HP; Weersink RA; Chen J; Kaji M; Kaga K; Matsui Y; Wilson BC; Zheng G; Yasufuku K
Lung Cancer; 2017 Nov; 113():59-68. PubMed ID: 29110850
[TBL] [Abstract][Full Text] [Related]
18. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
19. Differential expression of epithelial–mesenchymal transition and stem cell markers in intrinsic subtypes of breast cancer.
Pomp V; Leo C; Mauracher A; Korol D; Guo W; Varga Z
Breast Cancer Res Treat; 2015 Nov; 154(1):45-55. PubMed ID: 26467042
[TBL] [Abstract][Full Text] [Related]
20. Predictive Biomarker Profiling of > 6000 Breast Cancer Patients Shows Heterogeneity in TNBC, With Treatment Implications.
Millis SZ; Gatalica Z; Winkler J; Vranic S; Kimbrough J; Reddy S; O'Shaughnessy JA
Clin Breast Cancer; 2015 Dec; 15(6):473-481.e3. PubMed ID: 26051240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
